Antidote's best-in-class clinical trial search engine just got better for patients and caregivers looking to take part in celiac disease research
MIAMI, and PHILADELPHIA, Nov. 2, 2022 /PRNewswire-PRWeb/ -- Antidote Technologies (Antidote), a patient-centric digital engagement company focused on connecting patients with clinical research, today announced a collaboration with Beyond Celiac, the leading celiac disease organization working to drive diagnosis, advance research, and accelerate the discovery of new treatments and a cure. The collaboration leverages Antidote's best-in-class clinical trial search technology with Beyond Celiac's deep understanding of the condition and the motivation of patients living with celiac to participate in medical research. Ultimately, the goal of both organizations is to offer a patient-friendly journey that leads to better quality clinical trial search results.
Living with celiac disease can be difficult. It causes uncomfortable symptoms, impacts food choices, and creates anxiety in food settings. And, it can lead to damage to the small intestine's lining and impact the body's ability to absorb certain nutrients. That's why for the 1 in 133 Americans who live with celiac disease, new and better treatment options are critical.[1] There are more than 45 celiac disease clinical trials currently looking for such treatment options. But to fully enroll these studies, more than 245,000 patients would need to take part.[2]
"Living with celiac disease is a challenge faced by so many, but we believe research can change that," said Maria Luci, Director of Research Engagement at Beyond Celiac. "We're confident that better treatments are in our future, but patients need to take part in clinical trials in order to make that happen. Partnering with Antidote will help the celiac patient community find and connect to clinical trials in an easy and patient-friendly way."
For a long time, treatment for celiac disease focused on adopting and maintaining a gluten-free diet, but this comes with many challenges. Now, there are a variety of therapeutic approaches being studied, including breaking down gluten using enzymes, interrupting the effects of gluten on the cells lining the intestine, preventing the enzyme tTG from modifying gluten in the cell, inducing immune tolerance, and interrupting the immune reactions that occur.[3] Patients can match to these and more trials through the new search on the Beyond Celiac website powered by Antidote.
"We see the great unmet need in the celiac disease community, and we're honored to provide a custom search through Beyond Celiac," said Laurent Schockmel, CEO of Antidote. "We're grateful to Beyond Celiac for collaborating so closely with us to offer a superior clinical trial search experience for patients and caregivers affected by celiac disease."
To search for a celiac disease trial, visit the Beyond Celiac website. If you're interested in learning how you can offer patient-friendly clinical trial search on your website, please get in touch today.
About Antidote
Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to a shortage of suitable participants, Antidote uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit http://www.antidote.me.
About Beyond Celiac
Since 2003, Beyond Celiac has been the leading patient advocate and research-driven celiac disease organization working to drive diagnosis, advance research and accelerate the discovery of new treatments and a cure. By engaging with the top scientists in the field, awarding research grants, and supporting the community, Beyond Celiac envisions a world in which people with celiac disease can live healthy lives and eat without fear – a world Beyond Celiac.
Media contacts
Lisa Conroy, Head of Communications
Antidote
[email protected]
215-872-2917
Grace McElroy, VP of Patient Experience & Partnerships
Antidote
[email protected]
914-643-5260
Claire Baker, Senior Communications Director
Beyond Celiac
[email protected]
267-419-2111
References
[1] https://www.beyondceliac.org/celiac-disease/facts-and-figures
[2] https://www.clinicaltrials.gov/ct2/results?cond=celiac&term=&cntry=&state=&city=&dist=&recrs=a
[3] https://www.beyondceliac.org/research/drugdevelopment/drug-development-pipeline/
Media Contact
Lisa Conroy, Antidote, 1 2158722917, [email protected]
Claire Baker, Beyond Celiac, 267-419-2111, [email protected]
SOURCE Antidote Technologies
Share this article